Xpention Genetics, Inc. (OTC BB: XPNG) and Colorado State University have expanded their research agreement for collaboration in the development of a diagnostic cancer test for use on canines. The Amendment calls for Colorado State University to collect blood samples from living canines with cancer. The blood will be collected and processed for RNA preservation for use in the development of a molecular test for canine cancer detection by Xpention.
